Data Sheet 1_Cost-effectiveness analysis of gumarontinib versus savolitinib for the treatment of advanced or metastatic NSCLC with MET exon 14 skipping mutations in China using partitioned survival model.pdf

Background and objectivesBoth gumarontinib and savolitinib have demonstrated efficacy in treating non-small-cell lung cancer (NSCLC) with tumors harboring mesenchymal–epithelial transition factor gene exon 14 (METex14) skipping. However, the comparison of their efficacy and pharmacoeconomics profiles remains limited. This study aims to evaluate the cost-effectiveness of gumarontinib versus savolitinib for the treatment of METex14 skipping NSCLC in China.
MethodsA 3-state partitioned survival model (PSM) was developed with lifetime horizon from the perspective of Chinese healthcare system. Survival inputs were based on an unanchored matching-adjusted indirect comparison using individual patient data from GLORY trial to adjust for patient characteristics in NCT02897479. Costs and outcomes were discounted at an annual rate of 5%. Sensitivity and scenario analyses were conducted to explore model uncertainty.
ResultsGumarontinib gained an additional 0.10 QALYs at an incremental cost of $1,893 compared to savolitinib, resulting in the ICERs of $19,243/QALY, which is below the threshold of 3 times the GDP per capita in China ($35,007 per capita in 2022). Sensitivity and scenario analyses confirmed the robustness of the base-case results.
ConclusionGumarontinib is a cost-effective option compared to savolitinib for METex14 skipping NSCLC in China.

背景与研究目的：谷马替尼（gumarontinib）与赛沃替尼（savolitinib）均已被证实可有效治疗携带间质-上皮转化因子基因14号外显子（METex14）跳变的非小细胞肺癌（NSCLC）。但目前针对二者的疗效与药物经济学特征的对比研究仍较为有限。本研究旨在评估中国医疗卫生场景下，谷马替尼对比赛沃替尼治疗METex14跳变非小细胞肺癌的成本-效果。
研究方法：本研究从中国医疗卫生系统视角出发，构建了具有终身随访时限的三分区生存模型（PSM）。生存参数基于一项未锚定匹配调整间接比较，利用GLORY试验的个体患者数据，对NCT02897479试验中的患者特征进行校正。成本与结局均按5%的年贴现率进行贴现。此外，本研究开展了敏感性分析与场景分析，以探究模型的不确定性。
研究结果：相较于赛沃替尼，谷马替尼可额外获得0.10个质量调整生命年（QALYs），增量成本为1893美元，增量成本-效果比（ICER）为19243美元/质量调整生命年，低于中国2022年人均国内生产总值（GDP）3倍的阈值（35007美元/人）。敏感性与场景分析证实了基础案例结果的稳健性。
研究结论：在中国人群中，相较于赛沃替尼，谷马替尼是治疗METex14跳变非小细胞肺癌的一项具有成本-效果优势的治疗方案。